AbbVie Competitors

$116.38
+0.08 (+0.07 %)
(As of 08/2/2021 11:58 AM ET)
Add
Compare
Today's Range
$115.87
$117.33
50-Day Range
$111.40
$118.87
52-Week Range
$79.11
$119.15
Volume220,215 shs
Average Volume6.78 million shs
Market Capitalization$205.55 billion
P/E Ratio31.37
Dividend Yield4.47%
Beta0.82

AbbVie (NYSE:ABBV) Vs. JNJ, PFE, LLY, MRK, BMY, and ZTS

Should you be buying ABBV stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to AbbVie, including Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), and Zoetis (ZTS).

Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Risk and Volatility

Johnson & Johnson has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Johnson & Johnson and AbbVie, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson02702.78
AbbVie121202.73

Johnson & Johnson currently has a consensus price target of $190.3750, indicating a potential upside of 10.29%. AbbVie has a consensus price target of $121.2369, indicating a potential upside of 3.76%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities analysts plainly believe Johnson & Johnson is more favorable than AbbVie.

Earnings & Valuation

This table compares Johnson & Johnson and AbbVie's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.58 billion5.50$14.71 billion$8.0321.50
AbbVie$45.80 billion4.51$4.62 billion$10.5611.06

Johnson & Johnson has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

66.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 66.0% of AbbVie shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.5%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and AbbVie has raised its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Johnson & Johnson and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson19.92%37.06%14.04%
AbbVie12.40%150.27%14.04%

Summary

Johnson & Johnson beats AbbVie on 9 of the 16 factors compared between the two stocks.

Pfizer (NYSE:PFE) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Earnings & Valuation

This table compares Pfizer and AbbVie's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$41.91 billion5.87$9.62 billion$2.2219.80
AbbVie$45.80 billion4.51$4.62 billion$10.5611.06

Pfizer has higher earnings, but lower revenue than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Pfizer and AbbVie, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer010202.17
AbbVie121202.73

Pfizer currently has a consensus price target of $43.0833, indicating a potential downside of 1.97%. AbbVie has a consensus price target of $121.2369, indicating a potential upside of 3.76%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Pfizer.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.5%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Pfizer pays out 70.3% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 1 consecutive years and AbbVie has raised its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

64.1% of Pfizer shares are held by institutional investors. Comparatively, 66.0% of AbbVie shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pfizer and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer23.06%26.93%10.83%
AbbVie12.40%150.27%14.04%

Risk and Volatility

Pfizer has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Summary

AbbVie beats Pfizer on 14 of the 17 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Eli Lilly and and AbbVie's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$24.54 billion9.63$6.19 billion$7.9331.06
AbbVie$45.80 billion4.51$4.62 billion$10.5611.06

Eli Lilly and has higher earnings, but lower revenue than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Eli Lilly and and AbbVie, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and021112.93
AbbVie121202.73

Eli Lilly and currently has a consensus price target of $231.2857, indicating a potential downside of 6.10%. AbbVie has a consensus price target of $121.2369, indicating a potential upside of 3.76%. Given AbbVie's higher possible upside, analysts plainly believe AbbVie is more favorable than Eli Lilly and.

Dividends

Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

81.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 66.0% of AbbVie shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Eli Lilly and and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and23.91%132.28%16.36%
AbbVie12.40%150.27%14.04%

Volatility and Risk

Eli Lilly and has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Summary

Eli Lilly and beats AbbVie on 10 of the 18 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Merck & Co., Inc. pays out 43.8% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Merck & Co., Inc. and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.11.48%53.80%16.15%
AbbVie12.40%150.27%14.04%

Earnings and Valuation

This table compares Merck & Co., Inc. and AbbVie's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$47.99 billion4.05$7.07 billion$5.9412.94
AbbVie$45.80 billion4.51$4.62 billion$10.5611.06

Merck & Co., Inc. has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Merck & Co., Inc. and AbbVie, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.03802.73
AbbVie121202.73

Merck & Co., Inc. currently has a consensus price target of $94.7238, indicating a potential upside of 23.27%. AbbVie has a consensus price target of $121.2369, indicating a potential upside of 3.76%. Given Merck & Co., Inc.'s higher possible upside, equities research analysts plainly believe Merck & Co., Inc. is more favorable than AbbVie.

Institutional & Insider Ownership

71.7% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 66.0% of AbbVie shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Summary

AbbVie beats Merck & Co., Inc. on 9 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Volatility & Risk

Bristol-Myers Squibb has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Institutional & Insider Ownership

71.5% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 66.0% of AbbVie shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 2.9%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Bristol-Myers Squibb pays out 30.4% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Bristol-Myers Squibb and AbbVie, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb03912.85
AbbVie121202.73

Bristol-Myers Squibb presently has a consensus price target of $74.30, suggesting a potential upside of 8.34%. AbbVie has a consensus price target of $121.2369, suggesting a potential upside of 3.76%. Given Bristol-Myers Squibb's stronger consensus rating and higher possible upside, analysts clearly believe Bristol-Myers Squibb is more favorable than AbbVie.

Valuation & Earnings

This table compares Bristol-Myers Squibb and AbbVie's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$42.52 billion3.58$-9,015,000,000.00$6.4410.65
AbbVie$45.80 billion4.51$4.62 billion$10.5611.06

AbbVie has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bristol-Myers Squibb and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-11.44%37.76%13.14%
AbbVie12.40%150.27%14.04%

Summary

AbbVie beats Bristol-Myers Squibb on 12 of the 18 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Risk & Volatility

AbbVie has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Institutional & Insider Ownership

66.0% of AbbVie shares are owned by institutional investors. Comparatively, 90.0% of Zoetis shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. AbbVie pays out 49.2% of its earnings in the form of a dividend. Zoetis pays out 26.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Zoetis has increased its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for AbbVie and Zoetis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie121202.73
Zoetis06702.54

AbbVie presently has a consensus target price of $121.2369, suggesting a potential upside of 3.76%. Zoetis has a consensus target price of $188.75, suggesting a potential downside of 6.94%. Given AbbVie's stronger consensus rating and higher possible upside, equities research analysts plainly believe AbbVie is more favorable than Zoetis.

Valuation & Earnings

This table compares AbbVie and Zoetis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$45.80 billion4.51$4.62 billion$10.5611.06
Zoetis$6.68 billion14.43$1.64 billion$3.8552.68

AbbVie has higher revenue and earnings than Zoetis. AbbVie is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie12.40%150.27%14.04%
Zoetis25.30%55.11%14.70%

Summary

AbbVie beats Zoetis on 10 of the 17 factors compared between the two stocks.

pixel
Ad VEGI MGMT
Is This Small-Cap Company the Next Beyond Meat?
The plant-based food industry is gaining heat and this company may be the next big winner!

AbbVie Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.6$172.62+0.2%$454.58 billion$82.58 billion25.96
Pfizer logo
PFE
Pfizer
2.7$43.95+2.6%$246.02 billion$41.91 billion18.86Earnings Announcement
Analyst Report
Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.7$246.32+1.1%$236.23 billion$24.54 billion36.82Upcoming Earnings
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.8$76.84+0.0%$194.56 billion$47.99 billion35.09Earnings Announcement
Dividend Announcement
Analyst Report
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.5$68.58+1.0%$152.39 billion$42.52 billion-30.21Earnings Announcement
Short Interest Increase
Analyst Revision
Zoetis logo
ZTS
Zoetis
2.3$202.82+0.1%$96.29 billion$6.68 billion54.67Upcoming Earnings
Short Interest Decrease
Royalty Pharma logo
RPRX
Royalty Pharma
3.0$37.94+0.7%$23.03 billion$2.12 billion23.71Analyst Report
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$99.32+0.7%$22.32 billion$2.20 billion85.62Upcoming Earnings
Insider Selling
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.9$170.18+0.4%$9.68 billion$2.36 billion18.66Upcoming Earnings
Perrigo logo
PRGO
Perrigo
2.2$48.39+0.7%$6.46 billion$5.06 billion-28.46
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
2.2$16.13+2.1%$2.94 billion$152.91 million-6.75Upcoming Earnings
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.4$58.81+0.2%$2.59 billion$429.65 million17.71Upcoming Earnings
Corcept Therapeutics logo
CORT
Corcept Therapeutics
2.4$21.14+1.8%$2.47 billion$353.87 million27.82Earnings Announcement
Analyst Report
Analyst Revision
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
2.6$26.99+2.4%$1.43 billion$520.40 million13.04Upcoming Earnings
Short Interest Decrease
Endo International logo
ENDP
Endo International
2.2$5.10+0.8%$1.19 billion$2.90 billion12.75Upcoming Earnings
Omeros logo
OMER
Omeros
2.1$14.98+3.2%$933.67 million$73.81 million-6.14Upcoming Earnings
Zogenix logo
ZGNX
Zogenix
2.1$16.68+2.8%$930.96 million$13.64 million-3.88Upcoming Earnings
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
3.0$3.82+1.6%$376.35 million$156.47 million15.28Upcoming Earnings
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
2.1$5.28+1.5%$247.78 million$46.92 million-2.75Upcoming Earnings
Lannett logo
LCI
Lannett
2.5$4.64+0.0%$192.31 million$545.74 million-0.94Gap Up
Assembly Biosciences logo
ASMB
Assembly Biosciences
2.1$3.52+1.4%$141.36 million$79.11 million-2.07Upcoming Earnings
Short Interest Decrease
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
1.5$3.25+4.6%$48.91 million$37.44 million-23.21Short Interest Decrease
This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.